

## Special Issue

# Tumor Markers in Lung Cancer: Current Progress, Role in Targeted Therapy and Further Direction

### Message from the Guest Editor

Lung cancer is one of the leading cancer-related causes of death worldwide. The five-year survival rate of patients is around 50% without metastasis, while only about 5% of patients with distant tumors survive. Other than personal living habits, early diagnosis and proper treatment highly affect the quality of life of patients. Effective biomarkers could provide novel therapeutic opportunities, targeting therapy, immunotherapy, etc., that could significantly prolong the outcomes of patients. For example, overexpressed PD-L1 on the tumor surface is associated with metastasis of tumor cells, which leads to the development of anti-PD-L1 monoclonal antibodies or vaccines that block PD-1/PD-L1 signaling. This Special Issue will focus on publishing high-quality works related to the biomarkers for the early diagnosis of lung cancer, prediction of treatment resistance, and prevention of the recurrence of tumors that might raise and promote novel diagnostic and/or therapeutic strategies for daily clinical practice to benefit patients.

---

### Guest Editor

Prof. Dr. Qing Kay Li  
Department of Pathology, Johns Hopkins Medical Institutions,  
Baltimore, MD 21224, USA

---

### Deadline for manuscript submissions

closed (4 January 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/165358](https://mdpi.com/si/165358)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)